Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
코로나19 후보 벡터백신 MVA-SARS-2-S의 전임상 접종에서 면역원성과 효능
423
[키워드] acute respiratory syndrome
Adenovirus
Administered
Antigen
approved
binding
breath
candidate vaccine
cause
CD8
cellular
Characteristics
children
clinical evaluation
clinical experience
clinical trial
component
consequence
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 vaccines
disease
Ebola virus disease
economics
Efficacy
expresse
expressing
expression
full-length SARS-CoV-2
growth
Health
heterologous prime-boost
homologous
Human
human ACE2
Humoral immunity
immunization
immunocompromised individuals
immunogenicity
Infection
infectious agent
intramuscular
investigated
MERS-CoV
mice
Middle East
Middle East respiratory syndrome Coronavirus
modified vaccinia virus
neutralized
nonclinical testing
pandemic coronavirus
Phase I
poxvirus
produced
Protective
Protein
reached
resource
respiratory
respiratory syndrome coronavirus
robust
S protein
Safe
SARS-CoV-2
SARS-COV-2 infection
serum antibodies
serum antibody
Severe acute respiratory syndrome
Significance
smallpox vaccine
stability
T cell
T cells
vaccination
Vaccine
vaccine vector
vaccinia virus
vector
Virus Disease
[DOI] 10.1073/pnas.2026207118 PMC 바로가기 [Article Type] 423
[DOI] 10.1073/pnas.2026207118 PMC 바로가기 [Article Type] 423